Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine maintenance in MDS after intensive chemotherapy
NCT00446303Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2006
- Primary completion
- Jul 2010
- Countries
- 1
- Sponsor
- Groupe Français des Myélodysplasies
- Modality
- Small Molecules
- Drugs
- azacitidine
- Conditions
- myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Response Duration and Cumulative Incidence of Relapses. Started Jul 2006; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with high-risk MDS or secondary AML in CR or PR after intensive chemotherapy, not eligible for transplant.
04
Endpoints
Primary
Response Duration
Cumulative Incidence of Relapses
Beyond the preview
Go deeper on NCT00446303.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446303.